SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 ...
LAG-3 and TIGIT expression may predict skin melanoma progression and survival. Discover how these immune markers could shape ...
Checkpoint inhibitors are an anticancer drug that indirectly attacks tumors. They depend on infusions of antibodies to block proteins called immune checkpoints. Specifically, they target one of three ...
LAG-3 is identified as a potential biomarker for SCLC, aiding in patient stratification for ICI therapy. Higher LAG-3 expression in SCLC correlates with improved survival and increased immune activity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results